Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.55 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.41 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | ASPH | Q12797 | 2/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 5/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1016192 | 0.94 | HSD11B1 (0.53) | HSD11B1KDM6BKDM4AKDM4DKDM3B | |
| SCHEMBL13667474 | 0.87 | HSD11B1 (0.54) | HSD11B1MAPK8 | |
| SCHEMBL1018098 | 0.85 | HSD11B1 (0.54) | HSD11B1KDM4EHPGDNPC1GAA | |
| SCHEMBL1014864 | 0.78 | HSD11B1 (0.53) | HSD11B1KDM4EHPGDNPC1RAB9A | |
| SCHEMBL14667326 | 0.76 | HSD11B1 (0.47) | HSD11B1MAPK8NPC1SMN1; SMN2 | |
| SCHEMBL15718403 | 0.76 | GABRP (0.50) | KDM6BKDM4AKDM4DHIF1ANKDM2A | |
| SCHEMBL1015020 | 0.74 | HSD11B1 (0.52) | HSD11B1KDM6BKDM4AKDM4DKDM3B | |
| SCHEMBL28059199 | 0.73 | HSD11B1 (0.51) | HSD11B1KDM6BKDM4AKDM4DKDM3B | |
| SCHEMBL1014981 | 0.72 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL1014980 | 0.72 | HSD11B1 (1.00) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066335-A | Substituted pyrimidin-5-carboxamides 281 | ASTRAZENECA AB | 2011-05-18 | — | — | CN | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | HSD11B1 2/4885KDM6B 2447/4885KDM4A 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.